BIFIDO Co., Ltd.
Financials
Valuation Metrics
BIFIDO Co., Ltd.'s Market Cap is ₩201B. At end of 2025 it was ₩251B. Ranked #2263 of 2,405 in KR market (top 94%), #1500 of 1,627 on KOSDAQ (top 92%), #50 of 56 in Household & Personal Products (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 20.08B KRW | KR#2,263/2,405 Sec#50/56 |
| Revenue | 14.63B KRW | KR#2,209/2,405 Sec#49/56 |
| Net Income | 1.85B KRW | KR#1,422/2,405 Sec#34/56 |
| Total Assets | 64.21B KRW | KR#2,060/2,405 Sec#46/56 |
| Net Assets | 48.94B KRW | KR#1,915/2,405 Sec#42/56 |
| Employees | 101 | KR#1,623/2,405 Sec#34/56 |
| Value | ||
| P/E | 10.86x | KR#915/2,405 Sec#20/56 |
| P/B | 0.41x | KR#674/2,405 Sec#14/56 |
| P/S | 1.37x | KR#1,646/2,405 Sec#43/56 |
| FCF Yield | -16.15% | KR—/2,405 Sec—/56 |
| Profitability | ||
| ROE | 3.78% | KR#1,245/2,405 Sec#30/56 |
| ROA | 2.88% | KR#1,056/2,405 Sec#30/56 |
| Op. Margin | -6.99% | KR#1,912/2,405 Sec#45/56 |
| Revenue Growth | -15.44% | KR#2,039/2,405 Sec#50/56 |
| Financial Health | ||
| Debt Ratio | 31.22% | KR#608/2,405 Sec#19/56 |
| Total Debt | 10.00B KRW | KR#1,614/2,405 Sec#36/56 |
| FCF | -3.24B KRW | KR#1,398/2,405 Sec#39/56 |
| Cash | 7.61B KRW | KR#1,833/2,405 Sec#40/56 |
| Current Ratio | 2.50x | KR#683/2,405 Sec#18/56 |
| Performance | ||
| 1Y Return | -32.46% | KR#1,571/2,405 Sec#34/56 |
| 1M Return | -6.30% | KR#832/2,405 Sec#22/56 |
| From 52W High | -38.55% | KR#699/2,405 Sec#19/56 |
| 1Y MDD | -43.06% | KR#679/2,405 Sec#22/56 |
| Trading | ||
| Volume | 2,928 shares | KR#2,221/2,405 Sec#50/56 |
| Trading Value | 7.1M KRW | KR#2,284/2,405 Sec#54/56 |
| Foreign Own. | 0.78% | KR#2,108/2,405 Sec#46/56 |
| Per Share | ||
| EPS | 226 KRW | KR#1,252/2,405 Sec#32/56 |
| BPS | 5,982 KRW | KR#1,373/2,405 Sec#28/56 |
Company Info
Bifido, established in 1999 and listed on KOSDAQ in 2018, manufactures Bifidobacterium-based probiotics discovered in Korean infant intestines. It operates its own brand, Bifidolab, and provides domestic and international ODM services, possessing a proprietary patented strain, the sixth in the world to receive NDI and GRAS certifications from the US FDA. Through the development of MAP-based functional probiotics and eLBP microbiome therapeutics, Bifido is building a competitive pipeline targeting immune, cancer, and infectious diseases.